动态ROS响应的高分支聚合物基神经保护药物递送系统用于脑缺血性中风的病变发生适应性顺序治疗
Xutao Ma1, Xue Zhang1, Yanan Wang1
1College of Chemistry and Chemical Engineering, Ocean University of China, Qingdao, 266003, China.
Biomaterials
|September 13, 2025
概括
这项研究开发了一种用于治疗缺血性中风的新型纳米粒子输送系统. 该系统有效地向大脑输送药物,减少细胞死亡,并对抗神经炎症,显示出临床翻译的巨大潜力.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 神经科学是一个神经科学.
背景情况:
- 药物递送效率有限对缺血性中风治疗构成了挑战.
- 开发有针对性和响应性的药物输送系统对于有效的治疗至关重要.
研究的目的:
- 为了合成一种新型的ROS可切割的乙 (TA) 结合的高分支聚合物 (HBP) 用于向药物输送.
- 创建一个针对大脑的纳米粒子 (Bo-HBP(TA) NPs) 用于封装和输送拉巴素.
- 评价Bo-HBP (TA) NPs在治疗MCAO小鼠缺血性中风中的疗效.
主要方法:
- 通过'thiol-alkyne'点击化学合成了一种TA-链接的前体.
- 通过化交叉链接形成一个三维的HBP (TA).
- 结合了HBP(TA) 与玻利-PEG (Bo) 并自组装成Bo-HBP(TA) 的NP.
- 在NP中封装的拉巴胺用于MCAO小鼠的静脉注射.
主要成果:
- 博-HBP(TA) NPs有效地穿越了血脑屏障 (BBB),并在脑损伤中积累 (12.1% ID/g).
- 拉帕素的ROS反应释放激活了线粒和恢复了自,减少了96.9%的亡神经元.
- 治疗将微质重编程为抗炎性表型,并显著减少了心脏病发作区域 (至1.1%).
结论:
- 开发的Bo-HBP (TA) NP提供了一个有希望的,病原体适应的顺序性抗中风治疗策略.
- 纳米配方有效地减轻正在进行的ROS产生,抑制线粒体亡,并减少神经炎症.
- 这种方法证明了缺血性中风治疗的显著临床翻译潜力.
相关概念视频
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
139
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
139
01:23Modified-Release Drug Delivery Systems: Classification
320
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
320
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
186
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
186
01:24Modified-Release Drug Delivery Systems: Site-Targeted
167
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
167
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
167
01:26Oral Drug Delivery Systems: Continuous-Release Systems
323
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
323